收藏切换
Analysis on the current situation of listed innovative drugs in China from 2017 to 2020
收藏切换
Zijun TANG, Jiayu GUO, Jinyan TANG, Xiaohua YING*
World Clinical Drug | 2022, 43(3) : 294 - 299
Less
收藏切换
World Clinical Drug | 2022, 43(3): 294-299
• Article •
Analysis on the current situation of listed innovative drugs in China from 2017 to 2020
Full
Zijun TANG, Jiayu GUO, Jinyan TANG, Xiaohua YING*
Affiliations
  • School of Public Health, Fudan University, Shanghai 200032, China
Published: 2022-03-10 doi: 10.13683/j.wph.2022.03.015
Outline
收藏切换
Objective

According to analysis on the basic characteristics of listed innovative drug, market access and medical insurance access from 2017 to 2020 in China, we provided a reference for the early layout of the follow-up market and medical insurance decision-making.

Methods

The chemical innovative drugs and biological drugs listed in China from 2017 to 2020 were selected as the research object, and the differences in drug types, production attributes and evaluation items were analyzed from the aspects of overall situation, disease field and medical insurance access.

Results

The number of listed drugs increased steadily in the past four years. Among them, the number of chemical drugs was significantly higher than that of biological drugs, the number of imported drugs was significantly higher than that of domestic drugs, and the number of listed drugs, drugs entering the medical insurance catalogue and innovation review projects in the field of cancer were the largest.

Conclusion

In the future, chemical drugs will still occupy the dominant position in the market. Biopharmaceutical technology and domestic innovation ability need to be further improved. In popular areas such as oncology, drugs are more innovative and the access rate of drug medical insurance is also high.

innovative drug  /  drug review  /  market access  /  medical insurance access
唐紫君, 郭佳瑜, 汤金燕, 应晓华. 2017—2020年中国上市创新药物现况分析. 世界临床药物, 2022 , 43 (3) : 294 -299 . DOI: 10.13683/j.wph.2022.03.015
Zijun TANG, Jiayu GUO, Jinyan TANG, Xiaohua YING. Analysis on the current situation of listed innovative drugs in China from 2017 to 2020[J]. World Clinical Drug, 2022 , 43 (3) : 294 -299 . DOI: 10.13683/j.wph.2022.03.015
Year 2022 volume 43 Issue 3
14
4
Cite this Article
BibTeX
Article Info
doi: 10.13683/j.wph.2022.03.015
  • Receive Date:2022-01-06
  • Online Date:2026-11-19
  • Published:2022-03-10
Article Data
Affiliations
History
  • Received:2022-01-06
Affiliations
    School of Public Health, Fudan University, Shanghai 200032, China
References
Share
https://castjournals.cast.org.cn/joweb/sjlcyw/EN/10.13683/j.wph.2022.03.015
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT